

ESPS Peer-review Report

Name of Journal: World Journal of Gastroenterology

ESPS Manuscript NO: 5758

Title: Personalized cancer targeted therapy: fitting cancer treatment to different patient genome

Reviewer code: 02441494

Science editor: Gou, Su-Xin

Date sent for review: 2013-09-25 16:32

Date reviewed: 2013-09-26 23:03

CLASSIFICATION	LANGUAGE EVALUATION	RECOMMENDATION	CONCLUSION
<input type="checkbox"/> Grade A (Excellent)	<input type="checkbox"/> Grade A: Priority Publishing	Google Search:	<input type="checkbox"/> Accept
<input type="checkbox"/> Grade B (Very good)	<input checked="" type="checkbox"/> Grade B: minor language polishing	<input type="checkbox"/> Existed	<input checked="" type="checkbox"/> High priority for publication
<input checked="" type="checkbox"/> Grade C (Good)	<input type="checkbox"/> Grade C: a great deal of language polishing	<input type="checkbox"/> No records	<input type="checkbox"/> Rejection
<input type="checkbox"/> Grade D (Fair)	<input type="checkbox"/> Grade D: rejected	BPG Search:	<input type="checkbox"/> Minor revision
<input type="checkbox"/> Grade E (Poor)		<input type="checkbox"/> Existed	<input type="checkbox"/> Major revision
		<input type="checkbox"/> No records	

COMMENTS TO AUTHORS

The manuscript is useful for basic and clinical research. As understanding the molecular mechanisms in gastric cancer is important for clinical management strategy. But the quality of the figures in the manuscript is poor, especially the figures of microarray, please enhance them. Some of references are quite old, for example, the part of clinical use, please add some newest references.

ESPS Peer-review Report

Name of Journal: World Journal of Gastroenterology

ESPS Manuscript NO: 5758

Title: Personalized cancer targeted therapy: fitting cancer treatment to different patient genome

Reviewer code: 01560081

Science editor: Gou, Su-Xin

Date sent for review: 2013-09-25 16:32

Date reviewed: 2013-10-10 22:04

CLASSIFICATION	LANGUAGE EVALUATION	RECOMMENDATION	CONCLUSION
<input type="checkbox"/> Grade A (Excellent)	<input type="checkbox"/> Grade A: Priority Publishing	Google Search:	<input type="checkbox"/> Accept
<input checked="" type="checkbox"/> Grade B (Very good)	<input checked="" type="checkbox"/> Grade B: minor language polishing	<input type="checkbox"/> Existed	<input type="checkbox"/> High priority for publication
<input type="checkbox"/> Grade C (Good)	<input type="checkbox"/> Grade C: a great deal of	<input type="checkbox"/> No records	
<input type="checkbox"/> Grade D (Fair)	language polishing	BPG Search:	<input type="checkbox"/> Rejection
<input type="checkbox"/> Grade E (Poor)	<input type="checkbox"/> Grade D: rejected	<input type="checkbox"/> Existed	<input checked="" type="checkbox"/> Minor revision
		<input type="checkbox"/> No records	<input type="checkbox"/> Major revision

COMMENTS TO AUTHORS

The authors reviewed the up to date researches on the ontogenesis of gastric cancer. The manuscript might be helpful to clinicians to pick up a personalized cancer target therapy for gastric cancer patients. In order to do so, the author should include more data on clinical therapies which were designed according to well-known different molecular mechanisms of gastric cancer. The manuscript will be more persuasive if the self cited frequency can decline

ESPS Peer-review Report

Name of Journal: World Journal of Gastroenterology

ESPS Manuscript NO: 5758

Title: Personalized cancer targeted therapy: fitting cancer treatment to different patient genome

Reviewer code: 00505438

Science editor: Gou, Su-Xin

Date sent for review: 2013-09-25 16:32

Date reviewed: 2013-10-13 14:58

CLASSIFICATION	LANGUAGE EVALUATION	RECOMMENDATION	CONCLUSION
<input type="checkbox"/> Grade A (Excellent)	<input type="checkbox"/> Grade A: Priority Publishing	Google Search:	<input type="checkbox"/> Accept
<input type="checkbox"/> Grade B (Very good)	<input checked="" type="checkbox"/> Grade B: minor language polishing	<input type="checkbox"/> Existed	<input type="checkbox"/> High priority for publication
<input checked="" type="checkbox"/> Grade C (Good)	<input type="checkbox"/> Grade C: a great deal of language polishing	<input type="checkbox"/> No records	<input type="checkbox"/> Rejection
<input type="checkbox"/> Grade D (Fair)		BPG Search:	<input checked="" type="checkbox"/> Rejection
<input type="checkbox"/> Grade E (Poor)	<input type="checkbox"/> Grade D: rejected	<input type="checkbox"/> Existed	<input type="checkbox"/> Minor revision
		<input type="checkbox"/> No records	<input type="checkbox"/> Major revision

COMMENTS TO AUTHORS

Overall a very good summary of the current state of molecular pathology and targeting in gastric cancer, but little new information. Couple of issues 1. title should reflect the subject matter as being gastric cancer and needs revision 2. There is an overemphasis on the role of molecular markers with regards to targeted drug therapy. Surgery, medical oncology and radiotherapy are part of the continuum of multimodality therapy. Molecular targeting should also include the role of each of these therapies in multimodality therapy. For example, molecular targeting may indicate that any surgery is not beneficial in some types of overexpression, but at the same time, extremely aggressive surgical and chemotherapy including palliative surgery and peritomy may be indicated in other tumours expressing other markers. Although the concept is still in its infancy, this ideal represents the holy grail of personalised therapy and should at least be discussed. Reference number 39 refers to an unpublished study (notes that it has been submitted) This data should be excluded from the manuscript (last half of page 8 and first half of page 9) as it has not been peer reviewed